Dr. Yuanyuan Cheng has nearly 20 years of experience in health economics, health technology assessment (HTA), and health policy analysis. Dr. Cheng has served for the Pharmaceutical Benefits Advisory Committee (PBAC) of the Australian Department of Health, as well as global consulting firms such as Covance and Optum, where she was responsible for the development of market access strategy planning and value proposition optimization of pharmaceuticals, medical devices, and diagnostic technologies, etc. Dr. Cheng is actively engaged in the promotion of HTA policies and practices for innovative medicines in China following her returning to China in 2019. Dr. Cheng holds a Master's degree in Clinical Pharmacy from Sun Yat-sen Medical University and a PhD in Epidemiology and Health Economics from Curtin University, Australia.

Dr. Ge has over 20 years of global pharmaceutical industry experience and has held leading roles in drug discovery and development. Prior to founding Kangpu, Dr. Ge has worked at various US-based biotech and pharmaceutical companies, including Novartis, Schering-Plough and Celgene, and served in multiple roles with increasing responsibilities in medicinal chemistry and chemical development. He has authored/co-authored over 100 peer-reviewed scientific papers and patent applications. Dr. Ge received his PhD in Organic Chemistry from Rutgers University at New Brunswick, New Jersey, USA.

Mrs. Wang has over 15 years of clinical development experience in the pharmaceutical industry. Prior to joining Kangpu, Mrs. Wang served in clinical development leadership roles at various well-known biotech and pharmaceutical companies including AstraZeneca, Allergan, Kyowa Kirin, Celgene and Amgen. She has successfully led more than fifteen global clinical studies (Apremilast, Zilovertamab, Cariprazine, Milnacipran, Istradefylline, and Ticagrelor) ranging from Phase I to Phase IV in immunology, oncology, neurology, psychiatry, and cardiology, and led and supported multiple successful NDA/sNDA filings including Otezla, Vraylar and Nourianz. Mrs. Wang received her Master of Medicine from Peking University Health Science Center (formerly Beijing Medical University) and Master of Science from University of Notre Dame in the United States.

Mr. He is a research fellow, nationally certified consultant engineer and independent investor. His investments have involved areas such as construction engineering, energy, hotels, real estate development, and finance. He has achieved outstanding investment results and possesses strong entrepreneurial abilities, investment vision and rich business management experience. He holds a Master’s degree in Engineering from Southwest Jiaotong University and graduated from the program of Strategic Management and Capital Operation Chairman’s Class at Peking University.

Dr. Meng joined V-Capital in 2018. Prior to V-Capital, she worked at China State Institute of Pharmaceutical Industry and Shanghai Pudong Science and Technology Investment Co., Ltd.. She has profound experience in cross-border M&A and new drug investment. Dr. Meng holds a BS degree in Life Sciences from Fudan University and a PhD in Immunology from NCSU.

Dr. Song joined Northern Light Venture Capital (NLVC) in 2016. Prior to NLVC, he worked in the Department of Pharmacology and Department of Strategic Research at Staidson Biopharmaceutical Co., Ltd. Dr. Song has a profound understanding of China's pharmaceutical industry. He has extensive experiences not only in corporate strategic planning and implementation, but also in clinical regulatory affairs. Dr. Song holds a PhD in Biophysics from the Chinese Academy of Medical Sciences & Peking Union Medical College.

Mr. Xie joined Guozhong Venture Capital in 2019. He has focused on equity investments in the healthcare sector (including innovative medicines and medical devices). Mr. Xie has more than 10 years of rich experience in the pharmaceutical industry and venture capital investment combined. He has previously worked in Yangtze River Pharmaceutical (Group) Co., Ltd., Joincare Pharmaceutical Group Industry Co., Ltd. and Pusu Capital. Mr. Xie holds a Master’s degree in Medicinal Chemistry from Hunan University.

Ms. Zhang Shuping joined Lapam Capital in 2020. She has focused on early-stage investments in the field of innovative medicines. Ms. Zhang has 4 years of experience as a clinician, and nearly 10 years of experience in the multinational pharmaceutical companies. She holds a Master’s degree in Clinical Medicine (Internal Medicine) from Capital Medical University, and an Executive MBA Degree from Tsinghua and INSEAD.